Adicet Bio Files 8-K for Bylaw Amendments & Fiscal Year Change

TL;DR

Adicet Bio updated its bylaws and fiscal year end. No major financial news.

AI Summary

On December 26, 2025, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws, a change in its fiscal year, and other events. The company, formerly known as resTORbio, Inc., is incorporated in Delaware and headquartered in Boston, Massachusetts.

Why It Matters

This filing indicates potential structural or operational changes within Adicet Bio, Inc., which could impact its governance and financial reporting timeline.

Risk Assessment

Risk Level: low — The filing reports administrative and corporate governance changes, not material financial events or significant operational shifts.

Key Players & Entities

• Adicet Bio, Inc. (company) — Registrant
• resTORbio, Inc. (company) — Former company name
• December 26, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Boston, Massachusetts (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Capital M

Filing Documents

• acet-20251226.htm (8-K) — 63KB
• acet-ex3_1.htm (EX-3.1) — 17KB
• acet-ex99_1.htm (EX-99.1) — 20KB
• img94724212_0.jpg (GRAPHIC) — 5KB
• 0001193125-25-332343.txt ( ) — 227KB
• acet-20251226.xsd (EX-101.SCH) — 27KB
• acet-20251226_htm.xml (XML) — 5KB

03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 26, 2025, Adicet Bio, Inc. (the "Company") filed an amendment (the "Certificate of Amendment") to its Restated Certificate of Incorporation, to effectuate a reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). As previously disclosed, at its 2025 Special Meeting of Stockholders held on December 19, 2025 (the "Special Meeting"), and upon the recommendation of the Company's Board of Directors (the "Board"), the Company's stockholders approved a certificate of amendment to effect a reverse stock split of the Common Stock at a ratio ranging from any whole number between 1-for-5 and 1-for-30, as determined by the Board in its discretion, subject to the Board's authority to abandon such amendment (the "Charter Amendment"). The Charter Amendment was described in detail under "Proposal No. 1: Reverse Stock Split Proposal" beginning on page 5 of the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 17, 2025 (the "Proxy Statement") in connection with the Special Meeting. The text of the Charter Amendment was included in Appendix A of the Proxy Statement. On December 19, 2025, the Board approved a reverse stock split of the Common Stock at a ratio of 1-for-16. Effective as of 12:01 a.m. Eastern Time on December 30, 2025, the Company filed the Charter Amendment to effect a 1-for-16 reverse stock split of its shares of Common Stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, every 16 shares of the Company's Common Stock issued or outstanding were automatically reclassified into one validly issued, fully-paid and non-assessable new share of Common Stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Proportional adjustments were made to the number of shares

01 Other Events

Item 8.01 Other Events. On December 26, 2025, the Company issued a press release announcing the Reverse Stock Split and other related information. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. Cautionary Note Regarding Forward Looking Statements The disclosure in this Current Report on Form 8-K contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding the Company's expectations about the effects of the Reverse Stock Split, including the trading of the Company's common stock on The Nasdaq Capital Market following the Reverse Stock Split. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health crises on the Company's business and financial results, including with respect to disruptions to its preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a precl

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADICET BIO, INC. Date: December 29, 2025 By: /s/ Nick Harvey Name: Nick Harvey Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR